UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063721
Receipt number R000072917
Scientific Title Exploration of the feasibility of a conversational AI robot in people with dementia or mental disorders
Date of disclosure of the study information 2026/11/21
Last modified on 2026/11/21 15:38:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploration of the feasibility of a conversational AI robot in people with dementia or mental disorders

Acronym

Exploration of the feasibility of a conversational AI robot in people with dementia or mental disorders

Scientific Title

Exploration of the feasibility of a conversational AI robot in people with dementia or mental disorders

Scientific Title:Acronym

Exploration of the feasibility of a conversational AI robot in people with dementia or mental disorders

Region

Japan


Condition

Condition

Dementia, mild cognitive impairment (MCI), and mental disorders (primarily depressive disorders, bipolar disorder, schizophrenia spectrum disorders, and delusional disorder)

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To explore the feasibility, tolerability, safety, acceptability, conversational characteristics, and potential psychosocial effects of a generative AI-enabled conversational robot used by adults with dementia, MCI, or mental disorders in supervised outpatient/ward settings or at home. The study also aims to identify conditions for safe implementation and future research.

Basic objectives2

Others

Basic objectives -Others

feasibility, acceptability, and safety

Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

(1) Completion rate of the two-week home-use period: proportion of participants who complete the installation period without discontinuation and achieve 'successful use' (at least 20 minutes of conversation per day on at least three days per week; feasibility target: 80% or higher). Days when use is impossible due to travel, hospitalization, or other unavoidable reasons are excluded; time after dropout is treated as evaluable. (2) Occurrence of serious adverse events during study participation. (3) Completion rate of the planned approximately 10-minute conversational sessions in outpatient or ward settings.

Key secondary outcomes

(1) User experience, psychological responses, perceived burden, and barriers to implementation/continued use assessed through semi-structured interviews with participants, family/supporters, and healthcare staff. (2) Conversational continuity, interruption/refusal, days and duration of use, number of conversations, and duration per conversation. (3) Perceptions, acceptability, attachment, usability burden, and willingness to continue use assessed using questionnaires (CCR, B-LAPS-Ro, SUS).


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Participants use Sota, a tabletop conversational robot powered by generative AI. In outpatient/ward settings, a researcher or healthcare staff member supervises an approximately 10-minute session; a session may be extended to 20 minutes and repeated up to three times if requested and considered safe. Supportive conversation may include reminiscence and reflection on mood or daily activities. For home use, the robot is installed for approximately two weeks for unrestricted conversational use. Researchers conduct safety checks by telephone around day 2 and week 1. When independent reporting or discontinuation is difficult, family members or visiting nurses check the participant at least three times weekly.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Adults aged 18 years or older with dementia, MCI, or a mental disorder (primarily depressive disorders, bipolar disorder, schizophrenia spectrum disorders, or delusional disorder). (2) Written informed consent from the participant; if consent capacity is insufficient, written consent from a legally authorized representative after confirming the participant's wishes. (3) Eligibility is assessed considering psychiatric stability, conversational ability, and study-related risk.

Key exclusion criteria

(1) MMSE score below 10. (2) Severe disturbance of consciousness, delirium, marked agitation/refusal, risk of self-harm or harm to others, or clear suicidal ideation. (3) Acute physical illness or psychiatric symptoms making participation medically inappropriate. (4) Inability to converse in Japanese. (5) Severe hearing or speech impairment that prevents voice interaction. (6) High risk of worsened anxiety, confusion, delusional interpretation, dependency, or other psychiatric symptoms, as determined by investigators.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Yuto
Middle name
Last name Satake

Organization

Osaka University Graduate School of Medicine

Division name

Department of Psychiatry

Zip code

5650871

Address

D3, 2-2 Yamadaoka, Suita, Osaka, Japan

TEL

0668793051

Email

y.satake@psy.med.osaka-u.ac.jp


Public contact

Name of contact person

1st name Yuto
Middle name
Last name Satake

Organization

Osaka University Graduate School of Medicine

Division name

Department of Psychiatry

Zip code

565-0871

Address

D3, 2-2 Yamadaoka, Suita, Osaka, Japan

TEL

08057013682

Homepage URL


Email

y.satake@psy.med.osaka-u.ac.jp


Sponsor or person

Institute

The University of Osaka

Institute

Department

Personal name



Funding Source

Organization

The University of Osaka

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Review Board Osaka University Hospital

Address

2-2 Yamadaoka, Suita, Osaka

Tel

06-6210-8296

Email

rin-sokatu@dmi.med.osaka-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2026 Year 11 Month 21 Day

Date of IRB


Anticipated trial start date

2026 Year 12 Month 01 Day

Last follow-up date

2027 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2026 Year 11 Month 21 Day

Last modified on

2026 Year 11 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072917